Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7184587 | 0.98 | CYP4F2 (0.35) | CYP4F2CYP4A11 | |
| SCHEMBL26699654 | 0.81 | CYP4F2 (0.38) | CYP4F2CYP4A11 | |
| SCHEMBL1306106 | 0.79 | CYP4F2 (0.35) | CYP4F2CYP4A11 | |
| SCHEMBL4743712 | 0.77 | CHRM1 (0.38) | CYP4F2CYP4A11 | |
| SCHEMBL27390289 | 0.77 | CHRM1 (0.38) | CYP4F2CYP4A11 | |
| SCHEMBL6805224 | 0.77 | CTSL (0.33) | — | |
| Hydrochloric Acid SCHEMBL11403271 | 0.76 | CHRM1 (0.37) | CYP4F2CYP4A11 | |
| SCHEMBL1306326 | 0.75 | CYP4F2 (0.35) | CYP4F2CYP4A11 | |
| SCHEMBL1305982 | 0.75 | DGAT1 (0.40) | CYP4F2CYP4A11 | |
| SCHEMBL18905948 | 0.75 | CYP4F2 (0.40) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058857-A1 | Method of treating cancer | YAO SIU-LONG (US) | 2004-03-25 | — | — | US | disclosed |
| EP-1009420-B1 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO INC (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20020173451-A1 | Method of treating cancer | YAO SUI-LONG (US) | 2002-11-21 | — | — | US | disclosed |
| US-20020042375-A1 | Method of treating cancer | HEIMBROOK DAVID C (US) | 2002-04-11 | — | — | US | disclosed |
| US-20020041880-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2002-04-11 | — | — | US | disclosed |
| US-6127333-A | COMPRISING OLIGOPEPTIDES, HAVING AMINO ACID SEQUENCES THAT ARE SELECTIVELY PROTEOLYTICALLY CLEAVED BY FREE PROSTATE SPECIFIC ANTIGEN AND KNOWN CYTOTOXIC AGENTS, CHARACTERIZED BY A DIAMINE LINKER BETWEEN THE OLIGOPEPTIDE AND VINBLASTINE | MERCK & CO., INC. (US) | 2000-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042375-A1 | Method of treating cancer | ACP3, KLK3, FOLH1 | CYP4F2 3274/4885CYP4A11 800/4885 |
| US-20040058857-A1 | Method of treating cancer | KLK3, SHBG, ACP3 | CYP4F2 3108/4885CYP4A11 322/4885 |
| US-20020173451-A1 | Method of treating cancer | FOLH1, KLK3, ACP3 | CYP4F2 4129/4885CYP4A11 3040/4885 |
| US-20020041880-A1 | Method of treating cancer | ACP3, FOLH1, KLK3 | CYP4F2 3474/4885CYP4A11 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.